These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33781112)

  • 41. A Review of Novel Medical Treatments for Thyroid Eye Disease.
    Park JW; Yoon JS
    Korean J Ophthalmol; 2024 Jun; 38(3):249-259. PubMed ID: 38773958
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Teprotumumab-Induced Encephalopathy: A Rare Side Effect of a Novel Therapeutic.
    Yee MD; McCarthy J; Quinn B; Surani A
    WMJ; 2023 May; 122(2):134-137. PubMed ID: 37141481
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.
    Phansalkar R; Lu T; Alyono J; Lee J; Dosiou C; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):e101-e104. PubMed ID: 36877549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
    Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
    Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
    Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring.
    Belinsky I; Creighton FX; Mahoney N; Petris CK; Callahan AB; Campbell AA; Kazim M; Lee HBH; Yoon MK; Dagi Glass LR
    Ophthalmic Plast Reconstr Surg; 2022 Jan-Feb 01; 38(1):73-78. PubMed ID: 34085994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease.
    Xin Y; Xu F; Gao Y; Bhatt N; Chamberlain J; Sile S; Hammel S; Holt RJ; Ramanathan S
    Clin Pharmacokinet; 2021 Aug; 60(8):1029-1040. PubMed ID: 33768488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acquired Epiblepharon Alleviated With Teprotumumab Treatment in Active Thyroid Eye Disease Patient.
    Chen KW; Phelps PO
    Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):e195-e196. PubMed ID: 34269764
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
    Smith TJ; Janssen JAMJL
    Endocr Rev; 2019 Feb; 40(1):236-267. PubMed ID: 30215690
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
    Ding Y; Yang S; Gao H
    Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunotherapy for Graves' ophthalmopathy.
    Salvi M
    Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):409-14. PubMed ID: 25105999
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IGF-1R drugs travel from cancer cradle to Graves'.
    Dolgin E
    Nat Biotechnol; 2020 Apr; 38(4):385-388. PubMed ID: 32265558
    [No Abstract]   [Full Text] [Related]  

  • 53. Improvement of asymmetric thyroid eye disease with teprotumumab.
    Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
    Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist.
    Chen H; Shan SJ; Mester T; Wei YH; Douglas RS
    PLoS One; 2015; 10(6):e0130322. PubMed ID: 26087256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glycemic Trends in Patients with Thyroid Eye Disease Treated with Teprotumumab in 3 Clinical Trials.
    Smith TJ; Cavida D; Hsu K; Kim S; Fu Q; Barbesino G; Wester ST; Holt RJ; Bhattacharya RK
    Ophthalmology; 2024 Jul; 131(7):815-826. PubMed ID: 38253291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report.
    Singh G; Taylor B; Michalek S
    Cureus; 2023 Nov; 15(11):e48861. PubMed ID: 38111423
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A case of rapidly declining glycemic control and diabetic ketoacidosis in a newly diagnosed diabetes patient after starting teprotumumab for thyroid eye disease.
    Carter C; Marks M; Bundeff AW; Adewodu T; Alderman L
    Endocrine; 2024 Jan; 83(1):65-68. PubMed ID: 37725291
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Teprotumumab: a disease modifying treatment for graves' orbitopathy.
    Ting M; Ezra DG
    Thyroid Res; 2020; 13():12. PubMed ID: 32636936
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Objective Diplopia Outcomes for Patients Treated With Teprotumumab for Thyroid Eye Disease.
    Mudalegundi S; Huang P; Henderson AD; Carey AR
    J Neuroophthalmol; 2024 Mar; 44(1):80-86. PubMed ID: 38294416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Teprotumumab for the treatment of thyroid eye disease.
    Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
    Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.